Tofacitinib Citrate (CP-690550 citrate): Selective JAK3 Inhibitor for Immune Regulation Research

Executive Summary: Tofacitinib citrate (CP-690550 citrate) is a potent, selective JAK3 inhibitor with an IC₅₀ of ~1 nM for JAK3 and 20–100-fold weaker activity for JAK2 and JAK1, respectively [APExBIO]. It is widely applied in studies of lymphocyte proliferation, differentiation, and apoptosis through JAK-STAT pathway modulation [Strategic Frontiers in Immune Regulation]. Tofacitinib citrate suppresses IFN-γ and IL-4 during T cell differentiation, modulates IL-17 and Foxp3 expression, and is a gold standard for modeling autoimmune and inflammatory disorders [Strategic Advancements]. Comparative studies confirm its ability to reduce endothelial cell inflammation, though limitations exist regarding upregulation of adhesion molecules at higher concentrations (Zavoriti & Miossec 2025). APExBIO supplies Tofacitinib citrate (A4135) as a high-purity solid, supporting robust research workflows [APExBIO].

Biological Rationale

Janus kinase 3 (JAK3) is a hematopoietic cell-restricted tyrosine kinase critical for lymphocyte proliferation, differentiation, and survival. JAK3 transduces signals from cytokines such as interleukin-2 (IL-2), IL-4, IL-7, IL-9, IL-15, and IL-21 via the common gamma chain (γc) receptor, culminating in STAT activation and gene transcription [Tofacitinib Citrate: Selective JAK3 Inhibitor]. Dysregulated JAK-STAT signaling is linked to autoimmune diseases, including rheumatoid arthritis and certain cancers (Zavoriti & Miossec 2025). Modulation of this pathway, particularly through selective JAK3 inhibition, enables precise dissection of immune cell function, T cell subset differentiation, and cytokine-mediated responses. Tofacitinib citrate (CP-690550 citrate) has become a foundational tool in this field, enabling reproducible modeling of immune regulation and inflammatory disease mechanisms [Strategic Frontiers].

Mechanism of Action of Tofacitinib citrate (CP-690550 citrate)

Tofacitinib citrate is a potent, ATP-competitive inhibitor of JAK3 with an IC₅₀ of ~1 nM. It exhibits a 20-fold and 100-fold selectivity versus JAK2 and JAK1, respectively, with reported Ki values: JAK3 (6.5 nM), JAK2 (21.7 nM), JAK1 (1.6 nM) [APExBIO]. By preventing JAK3 autophosphorylation and downstream STAT activation, tofacitinib citrate disrupts cytokine signaling required for lymphocyte proliferation and differentiation [Navigating the Translational Frontier]. In T cell assays, it suppresses IFN-γ under Th1 differentiation and IL-4 under Th2 conditions, while modulating IL-17, Foxp3, and IL-10 in Th17 differentiation. The compound thus impacts immune cell lineage commitment and effector function without directly interfering with TNF or IL-17A signaling, which operate outside the JAK-STAT axis (Zavoriti & Miossec 2025).

Evidence & Benchmarks

• Tofacitinib citrate reduces IL-6 release from endothelial cells stimulated with TNF+IL-17A, demonstrating anti-inflammatory effects (Zavoriti & Miossec 2025, https://onlinelibrary.wiley.com/doi/10.1002/acr2.70081).
• At 1 μM, tofacitinib citrate diminishes upregulation of ICAM-1 and E-selectin in inflamed endothelial cells, but at 10 μM, it may enhance upregulation of VCAM-1 and ICAM-1 induced by TNF+IL-17A (Zavoriti & Miossec 2025, link).
• Tofacitinib citrate suppresses IFN-γ and IL-4 production in primary T cell differentiation assays at concentrations between 10 nM and 100 nM (APExBIO, https://www.apexbt.com/tofacitinib-cp-690550-citrate.html).
• Compound is soluble at ≥25.22 mg/mL in DMSO and ≥3.4 mg/mL in water (with gentle warming and ultrasonic treatment), but insoluble in ethanol (APExBIO, link).
• Stock solutions in DMSO remain stable for several months at <-20°C; long-term aqueous storage is not recommended (APExBIO, link).
• Comparative studies highlight that tofacitinib citrate, unlike pan-JAK inhibitors, does not provoke endothelial cytotoxicity at standard research concentrations (Zavoriti & Miossec 2025, link).

Applications, Limits & Misconceptions

Tofacitinib citrate is used for dissecting JAK-STAT signaling, immune cell function, and modeling inflammatory or autoimmune disorders. Its specificity enables modulation of Th1, Th2, and Th17 cell differentiation and cytokine production in vitro [Strategic Frontiers]. The compound is not effective in modulating direct TNF or IL-17A signaling, as these pathways are independent of JAK-STAT (Zavoriti & Miossec 2025). At supraphysiological concentrations (≥10 μM), paradoxical increases in adhesion molecule expression may occur, highlighting the importance of dose optimization. For cardiovascular safety research, tofacitinib citrate is less likely to induce endothelial cytotoxicity compared to pan-JAK inhibitors, but cannot prevent downregulation of thrombomodulin or all procoagulant shifts under inflammatory stress.

Common Pitfalls or Misconceptions

• Misconception: Tofacitinib citrate blocks all cytokine signaling.
  Clarification: It predominantly affects γc cytokine receptor signaling; TNF and IL-17A are unaffected.
• Pitfall: Using concentrations above 1 μM may lead to non-selective effects, including upregulation of VCAM-1 and ICAM-1 in endothelial models.
• Misconception: Compound is soluble in ethanol.
  Clarification: It is insoluble in ethanol; use DMSO or water with warming and sonication.
• Pitfall: Long-term storage of aqueous solutions can degrade compound integrity; DMSO stock storage at <-20°C is recommended.
• Misconception: All JAK inhibitors have equivalent effects on endothelial cells.
  Clarification: Comparative studies show unique cytotoxicity profiles; tofacitinib citrate is less cytotoxic than peficitinib or fedratinib.

For an extended protocol optimization guide, see "Tofacitinib Citrate in Immune Regulation: Workflows & Troubleshooting"; this article provides updated use-case boundaries and comparative evidence not covered in the workflows article. For a deep dive into the molecular rationale and translational context, "Strategic Frontiers in Immune Regulation" is extended here with new cardiovascular safety benchmarks. For a concise summary of selectivity and benchmarks, see "Tofacitinib Citrate: Selective JAK3 Inhibitor"; this page is updated here with recent endothelial cell findings.

Workflow Integration & Parameters

Tofacitinib citrate (A4135) from APExBIO is supplied as a solid and should be stored at -20°C. Prepare stock solutions at ≥25.22 mg/mL in DMSO or ≥3.4 mg/mL in water (warmed, with sonication). Avoid ethanol. Working concentrations for cellular assays typically range from 10 nM to 100 nM, selected based on cell type and endpoint. For endothelial cell studies, do not exceed 1 μM unless high-dose effects are specifically required (Zavoriti & Miossec 2025). For immune cell differentiation, titrate within the nanomolar range for optimal selectivity. DMSO stocks can be stored at -20°C for several months; prepare fresh working solutions as needed. For detailed workflows, see the APExBIO product page (Tofacitinib citrate (CP-690550 citrate)).

Conclusion & Outlook

Tofacitinib citrate (CP-690550 citrate) is a gold-standard, selective JAK3 inhibitor for immune regulation and inflammatory disorder research. Its nanomolar potency, predictable selectivity, and robust solubility profile make it essential for dissecting JAK-STAT signaling and modeling autoimmune disease mechanisms [APExBIO]. Comparative evidence confirms its utility in endothelial cell models and highlights appropriate dose boundaries. As immune regulation research advances, standardized protocols and critical benchmarking with compounds like tofacitinib citrate will further enable reproducible, translationally relevant insights into lymphocyte biology and inflammatory disease models.